ABBV AUG 2025ABBV is approaching a strong resistance zone after heavy selling volume near 210–215. The stock recently broke higher, but price is testing supply after a fast rally.
Institutional absorption was seen at 190 and 195, with 205 now acting as immediate support.
Upside target: 212–215 if buyers absorb
Key facts today
AbbVie (ABBV) announced a regular quarterly dividend of $1.64 per share, scheduled for payment on November 14, 2025, to shareholders recorded as of October 15, 2025.
AbbVie has signed a global licensing deal with Glenmark Pharma, paying $700 million for rights to develop and market the blood cancer drug ISB 2001 in key regions.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
2.11 USD
4.24 B USD
56.33 B USD
1.76 B
About AbbVie Inc.
Sector
Industry
CEO
Robert A. Michael
Website
Headquarters
North Chicago
Founded
2011
ISIN
US00287Y1091
FIGI
BBG0025Y4RY4
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
Related stocks
End of the Upward Impulse?
AbbVie is a large-cap healthcare company with ongoing sector-specific concerns.
Technically, impulsive upward waves seem to be completed.
Near-term indicators remain positive, but this optimism may only represent a point B.
Fair value for ABBV is around $190 and the current price reflects this.
Abbvie, maybe this time...
NYSE:ABBV has been very hard to trade...but with earnings behind us and good beat and guidance, I think this will run..
creating an ascending triangle here with higher highs into equal lows and a close above 197 next week could send this way past 200 IMO
healthcare sector is beaten down as it
Abbvie please go man lolNYSE:ABBV has tested my patience
has been in a downtrend for a while now and has finally broken out, is now above all MAs on the daily and above 50 SMA on the weekly
193 is a high volume node to cross and after that there is not much volume
targetting 200
ER coming up and expecting a very go
ABBV - Are you Ready?Hello TradingView Family / Fellow Traders. This is Richard, also known as theSignalyst.
📈ABBV has been in a correction phase and it is currently approaching the lower bound of the red and blue channels.
Moreover, the green zone is a strong round number $150 and structure!
🏹 Thus, the highlighte
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
ABBV5068386
AbbVie Inc. 4.05% 21-NOV-2039Yield to maturity
—
Maturity date
Nov 21, 2039
ABBV4911718
AbbVie Inc. 4.25% 21-NOV-2049Yield to maturity
—
Maturity date
Nov 21, 2049
ABBV5759203
AbbVie Inc. 5.05% 15-MAR-2034Yield to maturity
—
Maturity date
Mar 15, 2034
ABBV4693581
AbbVie Inc. 4.25% 14-NOV-2028Yield to maturity
—
Maturity date
Nov 14, 2028
ABBV5068390
AbbVie Inc. 4.75% 15-MAR-2045Yield to maturity
—
Maturity date
Mar 15, 2045
ABBV5758814
AbbVie Inc. 4.8% 15-MAR-2029Yield to maturity
—
Maturity date
Mar 15, 2029
ABBV4998675
AbbVie Inc. 4.75% 15-MAR-2045Yield to maturity
—
Maturity date
Mar 15, 2045
ABBV5759202
AbbVie Inc. 4.95% 15-MAR-2031Yield to maturity
—
Maturity date
Mar 15, 2031
ABBV5068389
AbbVie Inc. 4.85% 15-JUN-2044Yield to maturity
—
Maturity date
Jun 15, 2044
ABBV6009611
AbbVie Inc. 4.65% 15-MAR-2028Yield to maturity
—
Maturity date
Mar 15, 2028
ABBV5068387
AbbVie Inc. 4.25% 21-NOV-2049Yield to maturity
—
Maturity date
Nov 21, 2049
See all ABBV bonds
Curated watchlists where ABBV is featured.
Frequently Asked Questions
The current price of ABBV is 209.79 USD — it has decreased by −0.21% in the past 24 hours. Watch AbbVie Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NYSE exchange AbbVie Inc. stocks are traded under the ticker ABBV.
ABBV stock has risen by 2.19% compared to the previous week, the month change is a 7.77% rise, over the last year AbbVie Inc. has showed a 8.44% increase.
We've gathered analysts' opinions on AbbVie Inc. future price: according to them, ABBV price has a max estimate of 255.00 USD and a min estimate of 170.00 USD. Watch ABBV chart and read a more detailed AbbVie Inc. stock forecast: see what analysts think of AbbVie Inc. and suggest that you do with its stocks.
ABBV reached its all-time high on Mar 10, 2025 with the price of 218.66 USD, and its all-time low was 32.51 USD and was reached on Dec 17, 2012. View more price dynamics on ABBV chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
ABBV stock is 2.38% volatile and has beta coefficient of 0.36. Track AbbVie Inc. stock price on the chart and check out the list of the most volatile stocks — is AbbVie Inc. there?
Today AbbVie Inc. has the market capitalization of 375.50 B, it has increased by 1.37% over the last week.
Yes, you can track AbbVie Inc. financials in yearly and quarterly reports right on TradingView.
AbbVie Inc. is going to release the next earnings report on Oct 24, 2025. Keep track of upcoming events with our Earnings Calendar.
ABBV earnings for the last quarter are 2.97 USD per share, whereas the estimation was 2.88 USD resulting in a 3.12% surprise. The estimated earnings for the next quarter are 3.26 USD per share. See more details about AbbVie Inc. earnings.
AbbVie Inc. revenue for the last quarter amounts to 15.42 B USD, despite the estimated figure of 15.03 B USD. In the next quarter, revenue is expected to reach 15.55 B USD.
ABBV net income for the last quarter is 928.00 M USD, while the quarter before that showed 1.28 B USD of net income which accounts for −27.27% change. Track more AbbVie Inc. financial stats to get the full picture.
Yes, ABBV dividends are paid quarterly. The last dividend per share was 1.64 USD. As of today, Dividend Yield (TTM)% is 3.04%. Tracking AbbVie Inc. dividends might help you take more informed decisions.
AbbVie Inc. dividend yield was 3.54% in 2024, and payout ratio reached 263.15%. The year before the numbers were 3.87% and 220.33% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Sep 9, 2025, the company has 55 K employees. See our rating of the largest employees — is AbbVie Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. AbbVie Inc. EBITDA is 26.75 B USD, and current EBITDA margin is 44.40%. See more stats in AbbVie Inc. financial statements.
Like other stocks, ABBV shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade AbbVie Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So AbbVie Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating AbbVie Inc. stock shows the strong buy signal. See more of AbbVie Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.